Michael J. Fox Foundation for Parkinson's Research
Trial Pipeline
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
NCT07020026
Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)
NCT07265596
Parkinson Progression Marker Initiative Online (PPMI Online)
NCT05065060
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
NCT06719583
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™
NCT04507139
FoxBioNet: ECV (Extracellular Vesicle) 004
NCT04603326
Fox BioNet Project: LRRK2-002
NCT03545425
FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)
NCT03170063
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What the Pipeline for Michael J. Fox Foundation for Parkinson's Research Shows
According to the ClinicalTrials.gov registry, Michael J. Fox Foundation for Parkinson's Research is linked to 9 US clinical trials across every stage of research activity. Of those, 5 studies are currently recruiting — about 56% of the sponsor's indexed portfolio — and 3 are already marked complete, representing roughly 33% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Michael J. Fox Foundation for Parkinson's Research reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Michael J. Fox Foundation for Parkinson's Research is Parkinson Disease with 7 linked trials, and 2 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.